













Indication	Target	Candidate	Research	Hit	Lead	Pre-clinic	Phase I	Phase II	Sponsor / Licensee
FAP Expressing Tumors	Fibroblast Activation Protein (FAP)	FAP-2286	¹⁷⁷ Lu						 3B Pharmaceuticals Europe  CLOVIS ONCOLOGY US, RoW
			²²⁵ Ac						
			⁶⁸ Ga						
PDAC CRC, GBM, Ewing Sarcoma, Melanoma	Neurotensin Receptor (NTR)	FPI-2059 IPN-01087 3BP-227	²²⁵ Ac						 Fusion Pharmaceuticals Inc.
			¹⁷⁷ Lu						
			¹¹¹ In						
Neuroendocrine Tumors	Gastric Inhibitory Polypeptide Receptor (GIP-R)	3B-401							 3B Pharmaceuticals
		3B-402							
CAIX Expressing Tumors	Carbonic Anhydrase IX (CAIX)	Debio 0228							 Debiopharm
Solid Tumors	Undisclosed	NTA							 CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTB							 CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	NTC							 CLOVIS ONCOLOGY
Solid Tumors	Undisclosed	3BP							 3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP							 3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP							 3B Pharmaceuticals
Solid Tumors	Undisclosed	3BP							 3B Pharmaceuticals

 THERAPEUTIC RADIOPHARMACEUTICAL
 SPECT OR PET IMAGING AGENT